Tag: Biokhimik

New product from Promomed Group for protection, ensure the functioning and repair of the nervous system cells

Promomed Group has registered a new drug Brainmax®, reaffirming its commitment to the strategy of launching innovative, knowledge-based products....

Russian Ministry of Health included injectable Areplivir® in the guidelines for the treatment of COVID-19

The Ministry of Health of the Russian Federation has included the injectable form of the direct-acting antiviral drug Areplivir® (favipiravir)...

Biokhimik JSC of Promomed Group and Mordovia State University agreed on further cooperation

At the meeting of the management of Biokhimik JSC with Acting Rector of the Ogarev Mordovia State University Dmitry...

The first Russian injectable drug for treatment of COVID-19 is ap-proved

The first Russian direct-acting intravenous antiviral drug Areplivir® (favipiravir) received marketing authorization certificate and its supply to hospitals in...

Promomed Group and the Ministry of Economy, Trade and Entrepreneurship of the Republic of Mordovia signed an Agreement on the development of industrial tourism

On September 21, Biokhimik JSC (part of the Promomed Group) and the Ministry of Economy, Trade and Entrepreneurship of...

Areplivir developed by Promomed for the treatment of coronavirus infection received marketing authorization in Uzbekistan

Areplivir, included in the guidelines of the Ministry of Health of Russia for the treatment of COVID-19, received marketing...

Minister of Economic Development of the Russian Federation M. Reshetnikov took part in the launch of a production line at the Biokhimik plant of...

Maxim Reshetnikov visited the Biokhimik plant as part of acquaintance with the participants of the national project «Increasing labor...

PROMOMED GROUP and the Government of the Kyrgyz Republic agreed on cooperation

A memorandum of cooperation in the pharmaceutical field between the Ministry of Investment of the Kyrgyz Republic and PROMOMED...